Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  DAVE KAUSHIK J
 2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2011		 3. Issuer Name and Ticker or Trading Symbol
ANTARES PHARMA, INC. [AIS]
(Last)
(First)
(Middle)
250 PHILLIPS BLVD, SUITE 290		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Executive Vice President
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

EWING, NJ 08618		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 141,552 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (2) 05/13/2018 Common Stock 125,000 $ 0.85 D  
Stock Option (right to buy)   (2) 11/11/2018 Common Stock 175,000 $ 0.47 D  
Stock Option (right to buy)   (2) 12/04/2018 Common Stock 25,000 $ 0.37 D  
Stock Option (right to buy)   (2) 08/11/2019 Common Stock 25,000 $ 0.95 D  
Stock Option (right to buy)   (2) 11/11/2019 Common Stock 75,000 $ 1.1 D  
Stock Option (right to buy)   (2) 11/10/2020 Common Stock 75,000 $ 1.52 D  
Stock Option (right to buy)   (2) 05/16/2021 Common Stock 51,000 $ 1.66 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
DAVE KAUSHIK J
250 PHILLIPS BLVD
SUITE 290
EWING, NJ 08618		       Executive Vice President  

Signatures

Robert F. Apple as attorney-in-fact for Kaushik J. Dave 06/08/2011
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes: (i) 89,937 shares issued to and owned by Dr. Dave; (ii) 19,615 shares of restricted common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan that will vest 100% on February 22,2013; and (iii) 32,000 shares representing the target number of shares Dr. Dave may receive pursuant to the terms of the performance stock unit award made to Dr. Dave under the 2008 Equity Compensation Plan if certain performance goals are attained over the three-year period beginning January 1, 2011 and ending December 31, 2013 and Dr. Dave continues in employment with the Company through that period.
(2) The options vest in equal quarterly installments over three years beginning ten years prior to the expiration date.
 
Remarks:
Exhibit Index:
Exhibit 24, Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.